Efung Capital is a venture capital and private equity firm based in Shenzhen, China, founded in 2007. The firm specializes in early-stage and growth capital investments, particularly in the healthcare and life science sectors, focusing on biopharmaceuticals, high-end medical devices, and original drugs. Additionally, Efung Capital explores opportunities in technology, media, telecommunications, environmental protection, and new materials. The firm typically invests between RMB 5 million to RMB 50 million per transaction and aims to achieve exits through various channels, including initial public offerings, stock transfers, mergers, acquisitions, and management buyouts. With a strong research team and a track record of successful investments in more than 20 premium enterprises, Efung Capital has garnered recognition as a leading institution in the biomedical industry, enhancing its influence within the medical and life science sectors.
Turno is a fintech startup that provides electric vehicle solutions for operators and owners. It helps commercial vehicle operators make the switch to EVs. Turno accomplishes this by offering a diverse range of vehicles from partner OEMs, affordable financing, and battery value guarantees to ensure the best possible return on investment for EV owners. Turno's mission in India is to convert gasoline miles to electric miles. The startup sells EVs manufactured by various brands both online and in physical stores, as well as providing financing options and buying back used batteries.
IASO Biotherapeutics (IASO BIO) is a Nanjing-based biopharmaceutical company focused on the discovery, development and commercialization of cell therapies in the field of oncology.
Atom Bioscience is a clinical-stage biotechnology company developing new treatments for inflammatory and metabolic diseases such as chronic gout and non-alcoholic steatohepatitis.
Cloudbreak Therapeutics is a clinical-stage biotechnology company focusing on ocular drug development. Cloudbreak Therapeutics operates a capital efficient business model based upon VIC + 505b(2). We repurpose approved systemic drugs for ocular delivery to treat eye diseases and quickly advance drug candidates to complete proof-of-concept (POC) Phase II clinical trials and to out-license global rights for Phase III clinical trials, product registration, and commercialization. Fully embracing the pharmaceutical development ecosystem, we utilize contract research organizations (CRO) for non-clinical, CMC and clinical development to efficiently maximize capital for drug development.
Kind Pharmaceutical is a clinical-stage biopharmaceutical company that focuses on the discovery and development of anemia drugs. The company was founded in 2013 and is headquartered in Redwood City, California, United States.
Beino Bio is a China-based supplier of biopharmaceutical CDMO and cell culture media, providing process development and GMP production services for companies interested in introducing protein, cell therapy and gene therapy drugs to the Chinese and global markets.
JGene Biotechnology is a research and development biotechnology company dedicated to the research and development of universal CAR-NK/T products from iPS. It is hoped that the large-scale production of CAR-NK/T from iPS will provide cancer patients with spot-type, price-friendly, and affordable new immune cell therapy products. Recently received angel round investment.
Suns Bio Group offers new drug research and development, production, and sales. They offer innovative drugs, strive for high safety, high effectiveness, and a high success rate simultaneously, become a continuous innovator in the global biopharmaceutical field, and benefit patient groups.
3D Medicines, we use individual’s genetic information to prevent, diagnose, and treat cancer. We develop personalized medicines according to target population’s genetic background, to increase efficacy and safety.
Zifu Medical is a national high-tech enterprise focusing on the research and development, production, sales and service of high-end medical products for the digestive tract. The company has built a professional R&D team and an international R&D management platform, has undertaken a number of national and Shenzhen technological innovation projects, and has obtained more than 100 national patents. Insisting on independent innovation and adhering to the spirit of craftsmanship, the "Dasheng" magnetically controlled capsule endoscope system series products independently developed for ten years have obtained the National Medical Products Administration NMPA Class III medical device registration and EU CE certification (EC certificate) , Widely praised by medical institutions.
InnerMedical provides diagnosis and treatment solutions for the clinic in the field of major diseases. The company works on digestive tract and respiratory tract tumors, as well as cardiovascular diseases, and have completed the launch of the first domestic endoscopic ultrasonic diagnostic equipment, electronic endoscope, and medical image processing software platform through continuous technological solutions.
SiBionic develops and monetizes artificial intelligence for medical imaging and implantable medical devices. They are working on technologies including implanted retinal electrical stimulators, continuous glucose monitoring, sugar reticulum screening, gastric cancer screening, health management, managing chronic diseases, screening for diseases, diagnosing diseases, and treating diseases.
Harbour BioMed is a developer of bio-therapeutics aimed at immuno-oncology and inflammatory diseases. The company engages in discovery and development programs that are centered around two patented transgenic mouse platforms for generating both fully human monoclonal antibodies (H2L2) and heavy chain only antibodies (HCAb) based immune cell engager (HBICETM) bispecific antibodies, thereby enabling medical professionals to generate potential therapeutic antibodies and accelerate drug discovery and development.
Elicio Therapeutics is a pharmaceutical research company that develops an immuno-tumor vaccine to treat cancer. It offers potent vaccines and immunotherapies that enable precise targeting and delivery of immunogens directly to the lymphatic system, substantially enhancing the body's own system of immune defenses.
TriArm Therapeutics is a cell therapy company formed by Panacea Venture with R&D operations in Germany, United States and Greater China region. The company focuses on the research and clinical transformation of CD19 CAR-T product using non-viral gene transfer technology, which greatly reduces the cost and time of cell therapy product preparation, enabling better tumor therapy outcome.
Zhongyianke has launched a flu vaccine and is conducting clinical trials on four other human vaccines: a tetravalent influenza vaccine, a tetravalent meningococcal vaccine, a rabies vaccine, and a rubella vaccine. The company holds 14 China patents. In addition to its operations in Tianjin, the company has an R&D center in Beijing and a production facility in Liaoning Province.
Resverlogix Corporation, a biopharmaceutical company, focuses on the development of novel therapeutics in cardiovascular diseases, as well as in related indications in vascular inflammation and Alzheimer's disease. Its development programs include NexVas Plaque Regression, a technology platform, which has completed a Phase Ia safety trial in humans with RVX-208 and progressed to a Phase Ib/IIa clinical trial for the development of drugs that increase ApoA-I to reduce the risk of cardiovascular diseases; NexVas Vascular Inflammation, a discovery stage technology that is in preclinical stages for the development of drugs that target molecular markers of inflammation; NexVas Alzheimer's Disease, a discovery stage technology, which is in Phase I clinical trials for the development of drugs that enhance ApoA-I for the stabilization and regression of Beta Amyloid Plaque; ReVas, a research stage technology for the development of therapeutics to be used with medical devices for the treatment of cardiovascular diseases; and TGF-ß Shield, a preclinical stage therapeutic for the treatment of grievous proliferative diseases, such as cancer and fibrotic conditions. The company is headquartered in Calgary, Canada.
Chipscreen is a integrated biotech company specialized in discovery and development of novel small molecule pharmaceuticals. The company has utilized its proprietary chemical genomics-based discovery platform to successfully develop a portfolio of clinical and preclinical stage programs in a number of therapeutic areas. Our core competence is the science-driven approach in discovery, strong pipeline building capability, experience with IP, and regulatory expertise. Chipscreen's business strategy is to generate differentiated drug candidates across multiple therapeutic areas. Drug candidates are either developed by Chipscreen or co-developed and commercialized in a partnership at the research, preclinical and clinical stages. Chipscreen was established as Sino-foreign joint venture in 2001 by several highly regarded Chinese returnees from the United States with academic, scientific, and industrial experience. Our founders established our company out of a common vision to create the leading drug discovery and pharmaceutical in China
Lifotronic is a developer of physiotherapy and medical equipment designed to offer effective medical treatment and recovery system within the medical devices sector. The company's equipment includes liquid chromatography, nephelometry and lateral flow immunoassay, enabling healthcare providers to create value and improve the lives of patients.
Centrexion Therapeutics is a late clinical-stage biopharmaceutical company focusing on identifying, developing, and commercializing non-opioid and non-addictive therapies to address the treatment of chronic pain.
Aridis Pharmaceuticals discovers and develops anti-infectives to be used as add-on treatments to standard-of-care antibiotics. The company is utilizing its proprietary ʎPEXTM and MabIgX technology platforms to rapidly identify rare, potent antibody-producing B-cells from patients who have successfully overcome infection and to rapidly manufacture monoclonal antibodies (mAbs) for the therapeutic treatment of critical infections. These mAbs are already of human origin and functionally optimized for high potency by the donor's immune system; hence, they technically do not require genetic engineering or further optimization to achieve full functionality.
Founded in 2013, Frontier Biotechnologies is a commercial-stage biopharmaceutical company headquartered in China with global vision and world-class competitiveness. Frontier Biotech is committed to discovering, development, manufacturing, and commercialization of innovative medicines that improve patient health. Their medicines typically address the unmet medical needs of patients in the areas of anti-HIV treatment and pain management. Frontier Biotech's first commercial product was approved by the National Medical Product Administration (NMPA), which is the counterpart of the Food and Drug Administration (FDA) in China, in May 2018 through a priority review process and has gained accelerated approval. Two additional drug candidates are currently undergoing multiple clinical trials in Phase I and Phase II in both China and the United States. Frontier Biotech brings together many of the best scholars, scientists, and professionals in R&D, senior management, marketing, international business development, and manufacturing. At Frontier Biotech, their long-standing commitment to excellence is in everything they do throughthe entire development cycle from drug discovery, preclinical research to global clinical development. This approach has enabled Frontier Biotech to emerge in the global market as a competitive player in the field of HIV long-acting treatment and immunotherapy.
Founded in 2013, Frontier Biotechnologies is a commercial-stage biopharmaceutical company headquartered in China with global vision and world-class competitiveness. Frontier Biotech is committed to discovering, development, manufacturing, and commercialization of innovative medicines that improve patient health. Their medicines typically address the unmet medical needs of patients in the areas of anti-HIV treatment and pain management. Frontier Biotech's first commercial product was approved by the National Medical Product Administration (NMPA), which is the counterpart of the Food and Drug Administration (FDA) in China, in May 2018 through a priority review process and has gained accelerated approval. Two additional drug candidates are currently undergoing multiple clinical trials in Phase I and Phase II in both China and the United States. Frontier Biotech brings together many of the best scholars, scientists, and professionals in R&D, senior management, marketing, international business development, and manufacturing. At Frontier Biotech, their long-standing commitment to excellence is in everything they do throughthe entire development cycle from drug discovery, preclinical research to global clinical development. This approach has enabled Frontier Biotech to emerge in the global market as a competitive player in the field of HIV long-acting treatment and immunotherapy.
Ascentage Pharma develops novel small-molecule therapies for cancer, hepatitis B, and age-related diseases. They have developed a pipeline of seven drug candidates that disrupt complex and difficult-to-target protein-protein interactions and are next-generation tyrosine kinase inhibitors.
Castdservo provides solutions for the field of robots and intelligent equipment. They serve mobile phone manufacturing, battery manufacturing, metal processing, woodworking engraving, medical treatment, robotics, and other industries.
Rainjet is a medical equipment research and development manufacturer. They provide products and services for medical institutions, families, and individuals. The drafting units of the mandatory national pharmaceutical industry standard The psychophysiological lie detector measures, records, and analyses changes in the physiological indicators of the subject.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.